Mundipharma
Mario Verheijen is a seasoned professional with extensive experience in strategic marketing, sales management, and business development within the pharmaceutical and healthcare sectors. Currently serving as the Country Lead for Benelux at Mundipharma since June 2024, Mario has held key roles including Head of Marketing for BeneLux, the UK, and the Republic of Ireland at ALK Nederland, and Director of Marketing and Business Development at Vifor Pharma. Previous positions also include consulting roles at VC&I Management and P insight, as well as managerial positions at Brocacef and Nycomed (now Takeda Pharmaceuticals). Mario's education includes a Bachelor's degree in Physical Education from Fontys University of Applied Sciences and various professional courses in strategy and management.
This person is not in the org chart
This person is not in any offices
Mundipharma
5 followers
The Mundipharma global network of independent associated companies shares a common purpose to identify and accelerate the development of meaningful medicines that add value for patients and healthcare providers around the globe. Founded in the US by two physicians in 1952 and still privately owned, the network has a presence in over 120 countries. In Europe, the network employees more than 2,000 employees from R&D to manufacturing & supply and commercial, and with revenues in excess of €1 billion. At Mundipharma we strive for one high performing and learning environment where individuals can make a real difference. We have a strong track record of building successful alliances to license, develop and market medicines that improve patients’ lives, while also providing attractive options to financially constrained healthcare systems. Consistent with our entrepreneurial heritage, we like to think that we see what others don’t by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems. We have built a European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as diabetes, respiratory, oncology, pain and biosimilars.